| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/27/2005 | US20050020591 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds |
| 01/27/2005 | US20050020589 Tablet with protective coating; Parkinson's disease; sexual disorders |
| 01/27/2005 | US20050020585 Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| 01/27/2005 | US20050020584 Benzamide derivatives as antagonists of orexin receptors |
| 01/27/2005 | US20050020583 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 01/27/2005 | US20050020582 Optically active compounds clearing malformed proteins |
| 01/27/2005 | US20050020581 4H-quinazolinyl compounds; alkylation of a quinazoline with a 3-bromopiperidine-2,6-dione followed by alkylation with a heterocyclic alkyl compound; immunomodulators with increased solubility and chemical resistance to hydrolysis; alternatives to thalidomide treatment for autoimmune diseases |
| 01/27/2005 | US20050020580 Materials and methods for the prevention or treatment of apoptosis and apoptosis-related diseases and conditions |
| 01/27/2005 | US20050020578 Oxidoreductase enzyme inhibitors such as (R)-1-[4-(2-methyl-4-phenyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-pyrimidin-2-yl-ethanol, used as antidiabetic agents |
| 01/27/2005 | US20050020577 Method of treating lower urinary tract disorders |
| 01/27/2005 | US20050020576 Opioid antagonist; analgesics; antiinflammatory agents; side effect reduction |
| 01/27/2005 | US20050020575 Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands |
| 01/27/2005 | US20050020573 5HT2c receptor modulators |
| 01/27/2005 | US20050020572 Therapy for bacteria infections |
| 01/27/2005 | US20050020571 Antiserotonine agents; psycholgical disorders; headaches |
| 01/27/2005 | US20050020570 Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
| 01/27/2005 | US20050020569 Composition and method for treating erectile dysfunction and reducing fibrosis in erectile tissue of the human penis |
| 01/27/2005 | US20050020568 Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1] octane, the preparation thereof and the application of same in therapeutics |
| 01/27/2005 | US20050020567 Method of treating bacterial infections using gemifloxacin or a salt thereof and a carbapenem antibacterial agent |
| 01/27/2005 | US20050020564 Pyrazole-amides and sulfonamides as sodium channel modulators |
| 01/27/2005 | US20050020562 Drugs; analgesics; anesthetics; antiarrhythmia agents; antiinflammatory agents ; incontinence; gastrointestinal disorders; neurodegenerative disease |
| 01/27/2005 | US20050020558 Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics |
| 01/27/2005 | US20050020557 Synergistic mixture; anticancer agents; mammary glands |
| 01/27/2005 | US20050020556 Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes |
| 01/27/2005 | US20050020555 Estrogenic compounds as anti-mitotic agents |
| 01/27/2005 | US20050020554 Encasing estrogen in oxygen impervious container ; purging with inert gas; contraceptives; hormone replacement therapy |
| 01/27/2005 | US20050020553 Administering a steroid; diagnosis of pregnancy |
| 01/27/2005 | US20050020552 Pharmaceutical composition and method for transdermal drug delivery |
| 01/27/2005 | US20050020551 Using a compound containing gonand ring and a keto group |
| 01/27/2005 | US20050020550 Selective testicular 11beta-HSD inhibitors and methods of use thereof |
| 01/27/2005 | US20050020549 aqueous suspension; rhinitis therapy |
| 01/27/2005 | US20050020548 Viricides; aids therapy |
| 01/27/2005 | US20050020547 Compounds for the treatment of female sexual dysfunction |
| 01/27/2005 | US20050020546 Pharmaceutical compositions comprising active vitamin D compounds |
| 01/27/2005 | US20050020545 Substituted tetracycline compounds as antifungal agents |
| 01/27/2005 | US20050020544 Using pinene compound; prevention, therapy of autoimmune disease; antiarthritic agents; multiple sclerosis; lupus; antidiabetic agents; psoriasis; antihistamines; cardiovascular disorders; analgesics |
| 01/27/2005 | US20050020543 Hexa-citrated phytate and process of preparation thereof |
| 01/27/2005 | US20050020542 Method of modulating sodium ion absorption in epithelial cells |
| 01/27/2005 | US20050020541 Moderate neurotransmitters |
| 01/27/2005 | US20050020540 Biphenylcarboxylic amide derivatives as p38-kinase inhibitors |
| 01/27/2005 | US20050020539 Pharmaceutical compositions for the oral administration of heparin or derivatives thereof |
| 01/27/2005 | US20050020538 Composition for the prevention and/or treatment of disorders due to abnormal lipid metabolism, comprising propionyl L-carnitine and chitosan |
| 01/27/2005 | US20050020536 Highly pure fondaparinux sodium composition, process for preparing said composition and pharmaceutical compositions containing it as active principle |
| 01/27/2005 | US20050020534 Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites |
| 01/27/2005 | US20050020533 Ceramide analogs, process for their preparation and their use as antitumor agents |
| 01/27/2005 | US20050020530 Treatment of parkinson's disease with oligonucleotides |
| 01/27/2005 | US20050020523 Modified antisense nucleotides complementary to a section of the human haras gene |
| 01/27/2005 | US20050020522 Induce mitrosis and smooth muscle proliferation; administering to cell or tissue a polynucleotide which codes endothelial growth factor |
| 01/27/2005 | US20050020519 Increase concentration of peptide; controlling glucose uptake into cells; adjust metabolism; stimulate cell proliferation; reduce apoptosis; moderate gene expression' |
| 01/27/2005 | US20050020517 Treatment of HIV infection through combined administration of tipranavir and capravirine |
| 01/27/2005 | US20050020516 Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
| 01/27/2005 | US20050020515 Colorectal neoplasia prophylaxis |
| 01/27/2005 | US20050020512 In presence of acidic clay; coupling in presenc eof silver tetrafluoroborate ; anticancer agents |
| 01/27/2005 | US20050020511 Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus |
| 01/27/2005 | US20050020510 Prevent sperm and egg union; oral dosage; side effect reduction |
| 01/27/2005 | US20050020509 Process for preparing tannate liquid and semi-solid dosage forms |
| 01/27/2005 | US20050020504 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 01/27/2005 | US20050020503 Hepatitis C inhibitor compounds |
| 01/27/2005 | US20050020501 Administering bactericide; polypeptide antagonist such as rosolic acid |
| 01/27/2005 | US20050020500 Glycosaminoglycan-polypeptide complex; antiarthritic agents |
| 01/27/2005 | US20050020498 Apo-2 ligand/trail formulations |
| 01/27/2005 | US20050020495 Antiretroviral compositions comprising thymosin alpha peptides and protease inhibitors |
| 01/27/2005 | US20050020490 Eficiency purification of glucan, mannan, mannan-protein complex from yeasts; reducing antibiotics in animal feeds |
| 01/27/2005 | US20050020487 Therapy for anemia |
| 01/27/2005 | US20050020483 Sigma ligands for neuronal regeneration and functional recovery |
| 01/27/2005 | US20050020482 Methods for modulating gap junctions |
| 01/27/2005 | US20050020481 Ion channel modulating compounds and uses thereof |
| 01/27/2005 | US20050020480 Administering a steroid |
| 01/27/2005 | US20050019926 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same |
| 01/27/2005 | US20050019923 Nucleotide sequences comprising cationic polypropylenimine dendrimer and diaminobutane core for use as tool in delivery of drug agents and tissue targeted therapy |
| 01/27/2005 | US20050019921 Method for combined sequential agent delivery and electroporation for cell structures and use thereof |
| 01/27/2005 | US20050019892 Screening process for antibacterial agents |
| 01/27/2005 | US20050019889 Human osteoclast derived cathepsin |
| 01/27/2005 | US20050019872 PC-LECTIN protein; vaccines and diagnostic marker for prostate cancer |
| 01/27/2005 | US20050019854 Analyzing insulin response; solid phase synthesis; for treatment of prediabetes, hyperinsulinemia, and type II diabetes; kits |
| 01/27/2005 | US20050019835 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 01/27/2005 | US20050019830 Methods of screening for TRPM5 modulators |
| 01/27/2005 | US20050019812 Neutral amino acid transporter and gene thereof |
| 01/27/2005 | US20050019811 Neutral amino acid transporter and gene thereof |
| 01/27/2005 | US20050019794 Multilayered microfluidic apparatus for positioning protein crystal within an energy beam; high throughput assay; protein structure analysis |
| 01/27/2005 | US20050019783 Method of determining a chemotherapeutic regimen based on glutathione-s transferase pi expression |
| 01/27/2005 | US20050019768 Hepatocellular carcinoma-related genes and polypeptides, and method for detecting hepatocellular carcinomas |
| 01/27/2005 | US20050019743 Improved blood product suitable for use in transfusions comprising inhibitor of glycoprotein Ib alpha cleavage, such as a metalloproteinase or TACE inhibitor |
| 01/27/2005 | US20050019438 Nutraceuticals for treating physiological disorders related to perimonopause or menopause such as hot flashes; phytoestrogens |
| 01/27/2005 | US20050019436 Relieving pain at a body site by administering a dosage of capsaicinoid at the painful site without eliciting an effect outside the discrete location; local anesthetic effect; targeted therapy |
| 01/27/2005 | US20050019435 Administering a nutraceutic mixture containing berberine extracted from herbs, catalpol and oleanolic acid as active ingredients; treating diabetes, cholesterol elevation, and hyperglycemia |
| 01/27/2005 | US20050019433 Negatively charged polysaccharide derivable from aloe vera |
| 01/27/2005 | US20050019431 Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof |
| 01/27/2005 | US20050019430 Non-toxic mucosal disinfectant containing isopropyl alcohol, sesame oil, aloe, and lemon oil |
| 01/27/2005 | US20050019429 Administering therapeutically-effective amount of Quercetin or Quercetin Glycosides(extracted from plant source selected from onions and apples) and Epican Forte(mixture of proline, lysine, arginine, vitamin c, n-acetylcystein, selenium, copper, magnesium, manganese) |
| 01/27/2005 | US20050019427 Composition for stimulation of specific metallo-enzymes |
| 01/27/2005 | US20050019424 Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives |
| 01/27/2005 | US20050019423 Method for treating amyotrophic lateral sclerosis |
| 01/27/2005 | US20050019422 Two therapeutical active agents are not contacting from one another, each by entrapping in a multiplicity of particles or beads; a carboxylic acid, or a salt or ester thereof; peroxides; stability |
| 01/27/2005 | US20050019418 Wart treatment |
| 01/27/2005 | US20050019417 stabilization of proteins, peptides or cells by fluidization of microparticles to form fluidized bed of microparticles comprising water soluble gel forming solid particles, then spraying coating with liquids comprising sugars and solvents, and drying |
| 01/27/2005 | US20050019413 Composition of matter comprising particles which contain choline chloride to be administered in a rumen protected and post-ruminally effective form |
| 01/27/2005 | US20050019409 Gastric retention dosage form having multiple layers |
| 01/27/2005 | US20050019408 time-release agents comprising water-swellable matrix cores containing estrogen derivative extracted from animals surrounded by film-forming coatings |
| 01/27/2005 | US20050019407 Composite dosage forms |